Rationale: Several guidelines exist that address treatment of patients with nonmetastatic muscle-invasive bladder cancer (MIBC). However, most only briefly mention follow-up strategies for patients and hence the treating physician is often left to infer on what the preferred follow-up schema would be for an individual patient. Herein, we aim to synthesize recommendations for follow-up of patients with MIBC for easy reference. Methods: A multidisciplinary MIBC expert panel from the International Bladder Cancer Network was assembled to critically assess currently available major guidelines on surveillance of MIBC patients. Recommendations for follow-up were extracted and critically evaluated. Important considerations for guideline assessment included both aspects of oncological and functional follow-up—frequency of visits, the use of different imaging modalities, the role of cytology and molecular markers, and the duration of follow-up. Outcome: An International Bladder Cancer Network expert consensus recommendation was constructed for the follow-up of patients with MIBC based on the currently available evidence-based data.
|Number of pages||9|
|Journal||Urologic Oncology: Seminars and Original Investigations|
|Early online date||2 Mar 2018|
|Publication status||Published - Sept 2018|
Bibliographical notePublisher Copyright:
© 2018 Elsevier Inc.
Data Availability StatementSupplementary data associated with this article can be
found in the online version at http://dx.doi.org/10.1016/j.
- Bladder cancer
- Disease management
- Muscle invasive